Schlusskurs
Andere Börsenplätze
|
||
- GBX | - |
09.05. | Verona Pharma unterzeichnet Finanzierungsvereinbarungen über bis zu 650 Millionen Dollar | MT |
09.05. | Verona Pharma-Aktien fallen nach größerem Q1-Verlust | MT |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 59 | 01.02.20 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 01.03.20 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.23 |
Tara Rheault
CTO | Chief Tech/Sci/R&D Officer | 49 | 01.01.19 |
Kathleen Rickard
CTO | Chief Tech/Sci/R&D Officer | 65 | 01.02.19 |
Victoria Stewart
IRC | Investor Relations Contact | - | 01.02.19 |
Corporate Officer/Principal | - | 01.06.20 | |
Ostra Jewell
HRO | Human Resources Officer | - | 01.09.22 |
Caroline Diaz
LAW | General Counsel | - | 01.10.21 |
Matthew Casbon
SAM | Sales & Marketing | - | 24.08.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 17.06.16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 12.09.16 |
David Ebsworth
CHM | Chairman | 69 | 01.12.14 |
Director/Board Member | 71 | 10.09.15 | |
Martin Edwards
BRD | Director/Board Member | 68 | 01.04.19 |
Director/Board Member | 68 | 10.09.15 | |
Chief Executive Officer | 59 | 01.02.20 | |
Director/Board Member | 59 | 01.09.23 | |
Lisa Deschamps
BRD | Director/Board Member | 52 | 01.03.21 |
James Brady
BRD | Director/Board Member | 61 | 14.03.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 608 138 246 | 458 671 402 ( 75,42 %) | 0 | 75,42 % |
Unternehmenskontakt
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+3.91% | 109 Mrd. | |
+10.87% | 105 Mrd. | |
+1.28% | 22.25 Mrd. | |
-13.14% | 22.09 Mrd. | |
-7.05% | 18.68 Mrd. | |
-38.36% | 17.58 Mrd. | |
-10.66% | 16.85 Mrd. | |
+3.75% | 13.76 Mrd. | |
+36.70% | 12.46 Mrd. |
- Börse
- Aktien
- A2N39N Aktie
- Aktie
- Unternehmen Verona Pharma Plc